Due to the molecular complexity of cancer, combination therapy is becoming increasingly important for better
long-term prognosis with fewer side effects. To further increase the therapeutic effects, advanced drug delivery systems
(DDSs), capable of simultaneously delivering multiple drugs to the site of action with specific time-programmed release
profiles, are important requirements. Nanocarriers for the simultaneous co-delivery of multiple chemical drugs in combination
therapy have been extensively reviewed. Here we focus on the nanotechnology enabled DDSs for the simultaneous
co-delivery of therapeutic genes and chemical drugs for cancer treatment. The opportunities for this combination strategy
and their challenges will be discussed.
Keywords: Cancer, co-delivery, drug delivery, liposomes, mesoporous silica nanoparticles, nanocarriers, siRNA.
Rights & PermissionsPrintExport